Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Rifaximin plus cefotaxime versus cefotaxime alone in treatment of spontaneous bacterial peritonitis in patients with cirrhosis

The Egyptian Journal of Internal Medicine volume 30, pages 154–159 (2018)Cite this article

Abstract

Background/purpose of the study

Spontaneous bacterial peritonitis (SBP) is a cause of significantly higher morbidity and mortality in patients with cirrhosis. This study was conducted to assess the effect of adding rifaximin to cefotaxime in treatment of SBP.

Materials and methods

The study was a prospective one that involved 98 patients with cirrhosis with SBP, who were divided randomly into two equal groups. Patients in group I received cefotaxime, whereas patients in group II received a combination of cefotaxime and rifaximin. Patients were evaluated clinically, and diagnostic aspiration was repeated on the third day of antibiotic therapy.

Results

Both groups showed significant reduction in white blood cells on the third day compared with the first day (P<0.0001). Polymorphonuclear leukocyte count in ascetic fluid in both groups showed significant reduction on the third day compared with the first day, and the reduction was statistically significant in group II compared with group I (P<0.0001). One the third day of therapy, serum creatinine levels in group I and group II were 1.61±0.19 and 1.28±0.37, respectively. Both groups showed significant decrease in serum creatinine level. The reduction in group II compared with group I was statistically significant, with P value less than 0.0001.

Conclusion

Rifaximin plus cefotaxime showed some favorable effects in treatment of SBP than cefotaxime alone. However, the clinical effects of these effects need to be clarified in further studies.

References

  1. Giannelli V, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, Thalheimer U. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol 2014; 20:16795.

    Article  Google Scholar 

  2. Nousbaum JB, Cadranel JF, Nahon P, Khac EN, Moreau R, Thévenot T, et al. Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology 2007; 45:1275–1281.

    Article  Google Scholar 

  3. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998; 28:1187–1190.

    Article  CAS  Google Scholar 

  4. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997; 26:1372–1378.

    Article  CAS  Google Scholar 

  5. Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9:727–738.

    Article  Google Scholar 

  6. Rimola A, Salmerón JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995; 21:674–679.

    Article  CAS  Google Scholar 

  7. Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol 2011; 17:1237.

    Article  Google Scholar 

  8. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010; 26:17.

    Article  CAS  Google Scholar 

  9. De Leo C, Eftimiadi C, Schito G. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12:979–981.

    PubMed  Google Scholar 

  10. Debbia E, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra-and sub-inhibitory concentrations. J Chemother 2008; 20:186–194.

    Article  CAS  Google Scholar 

  11. Brigidi P, Swennen E, Rizzello F, Bozzolasco M, Matteuzzi D. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002; 14:290–295.

    Article  CAS  Google Scholar 

  12. Xu D, Gao J, Gillilland M, Wu X, Song I, Kao JY, Owyang C. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 2014; 146:484–496.

    Article  CAS  Google Scholar 

  13. Ginés P, Angeli P, Lenz K, Møller S, Moore K, Moreau R. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53:397–417.

    Google Scholar 

  14. Hanouneh MA, Hanouneh IA, Hashash JG, Law R, Esfeh JM, Lopez R, et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 2012; 46:709–715.

    Article  CAS  Google Scholar 

  15. Rogers GB, van der Gast CJ, Bruce KD, Marsh P, Collins JE, Sutton J, Wright M. Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertension. PLoS One 2013; 8:e74884.

    Article  CAS  Google Scholar 

  16. Reuken P, Pletz M, Baier M, Pfister W, Stallmach A, Bruns T. Emergence of spontaneous bacterial peritonitis due to enterococci-risk factors and outcome in a 12-year retrospective study. Aliment Pharmacol Ther 2012; 35:1199–1208.

    Article  CAS  Google Scholar 

  17. Umgelter A, Reindl W, Miedaner M, Schmid R, Huber W. Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 2009; 37:2–8.

    Article  CAS  Google Scholar 

  18. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60:1310–1324.

    Article  Google Scholar 

  19. Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56:S1–S12.

    Article  Google Scholar 

  20. Piano S, Salinas F, Morando F, Cavalin M, Romano A, Rosi S, et al. Poster Session 1: infections and acute on chronic liver failure. Abstract 574: the empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis: results of a randomized controlled clinical trial. Hepatology 2014; 60:478A–501A.

    Google Scholar 

  21. Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: pros and cons. World J Gastrointest Pharmacol Ther 2012; 3:62.

    Article  Google Scholar 

  22. Koulaouzidis A, Bhat S, Karagiannidis A, Tan W, Linaker B. Spontaneous bacterial peritonitis. Postgrad Med J 2007; 83:379–383.

    Article  CAS  Google Scholar 

  23. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, Xourgia X, Tsianos EV. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 2012; 10:815–818.

    Article  CAS  Google Scholar 

  24. Zapater P, Caño R, Llanos L, Ruiz-Alcaraz AJ, Pascual S, Barquero C, et al. Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis. Gastroenterology 2009; 137:1669–1679.

    Article  CAS  Google Scholar 

  25. Tandon P, Garcia-Tsao G. Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2011; 9:260–265.

    Article  Google Scholar 

  26. Wong F, O’Leary JG, Reddy KR, Patton H, Kamath PS, Fallon MB, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 2013; 145:1280–1288.

    Article  Google Scholar 

  27. Runyon BA, Borzio M, Young S, Squier SU, Guarner C, Runyon MA. Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis. Hepatology 1995; 21:1719.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Tropical Medicine and Gastroenterology, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt

    Asmaa N. Mohammad MD (Assistant Professor) & Amr M. Zaghloul

  2. Department of Pharmacology, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt

    Walaa I. Mohammed

  3. Department of Medical Microbiology and Immunology, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt

    Hameda H. Mohamed

  4. Department of Gastroenterology Division, Department of Internal Medicine, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt

    Mahmoud K. Elsamman

Authors
  1. Asmaa N. Mohammad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahmoud K. Elsamman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amr M. Zaghloul
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hameda H. Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Walaa I. Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Asmaa N. Mohammad MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohammad, A.N., Elsamman, M.K., Zaghloul, A.M. et al. Rifaximin plus cefotaxime versus cefotaxime alone in treatment of spontaneous bacterial peritonitis in patients with cirrhosis. Egypt J Intern Med 30, 154–159 (2018). https://doi.org/10.4103/ejim.ejim_19_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_19_18

Keywords